Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 39 of 39 publications.

Ling C, Hawe E, Stevenson A, Low EW. Giving voice to rare diseases during joint clinical assessment (JCA). Presentation to be given at the ISPOR Europe 2024; November 20, 2024. Barcelona, Spain.

Leonard C, Unsworth H, Warttig S, Gildea L, Mordin M, Ling C. HTA considerations for large language models in healthcare. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Leonard C, Bhogal P, Menon AP, Ling C, Mordin M. HTA requirements for medical technologies in Spain. Poster to be given at the ISPOR Europe 2024; November 17, 2024. Barcelona, Spain.

Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. HTA requirements for medical technologies in Canada. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S286. doi: 10.1016/j.jval.2024.03.1564

Mordin M, Bhogal P, Warttig S, Gildea L, Long J, D'Souza V, Kinderas M, Ling C, Hartley L. What is the medical technology HTA process in Japan? Poster presented at the ISPOR 2024; May 6, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S284. doi: 10.1016/j.jval.2024.03.1554

Krause T, Fleming A, Hurst M, Zema C, Costello J, Hawe E, Ling C. Prognostic factors and surrogate endpoints in obstructive hypertrophic cardiomyopathy: a systematic literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S36. doi: 10.1016/j.jval.2023.09.189

Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Warttig S, Hartley L, Ling C. Understanding how health technology assessment bodies select medical technology for review: results of an online survey. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S432. doi: 10.1016/j.jval.2023.09.2258

D'Souza V, Gildea L, Mordin M, Long J, Kinderås M, Ling C, Warttig S, Hartley L. Differences and similarities of health economic evaluation for medical technologies by HTA bodies. Poster presented at the ISPOR Europe 2023; November 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S438. doi: 10.1016/j.jval.2023.09.2287

Mordin M, Gildea L, Long J, D'Souza V, Kinderås M, Ling C, Warttig S, Hartley L. What evidence should medical technology companies expect HTA bodies to review? Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S431. doi: 10.1016/j.jval.2023.09.2254

Mordin M, Warttig S, Gildea L, Long J, D'Souza V, Kinderås M, Ling C, Hartley L. Digging into the medical technology HTA process in Tunisia. Poster presented at the ISPOR Europe 2023; November 13, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S429. doi: 10.1016/j.jval.2023.09.2242

Lanne G, Kinderås M, Ling C, Brodtkorb TH. How much does TLV value rarity? A review of reimbursement decisions on orphan drugs in Sweden from 2017 through 2022. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S201. doi: 10.1016/j.jval.2023.09.1028

Kinderås M, Gildea L, Mordin M, Long J, D'Souza V, Ling C, Warttig S, Hartley L. Submission process and requirements of Nordic health technology assessment organisations for medical technologies: results of an online survey. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S435. doi: 10.1016/j.jval.2023.09.2272

Hartley L, Gildea L, Mordin M, Long J, D'Souza V, Kinderås M, Ling C, Warttig S. Does real-world evidence play a role in decision-making by HTA bodies for medical technologies? Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 supplement):S434-5. doi: 10.1016/j.jval.2023.09.2271

Mordin M, Gildea LJ, Warttig S, Costello J, D'Souza V, Kinderås M, Ling C, Marcano Belisario J. HTA processes for medical technologies across the world – are all hurdles the same? Poster presented at the ISPOR 2023 Conference; May 8, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S272-3. doi: 10.1016/j.jval.2023.03.1503

Costello J, D'Souza V, Gildea L, Kinderås M, Ling C, Belisario JM, Warttig S. Process and requirements for submitting nonpharmaceutical medical technologies to health technology assessment authorities. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S386. doi: 10.1016/j.jval.2022.09.1915

Warttig S, Ling C. Health technology assessment (HTA) methods for monoclonal antibodies for treatment and prevention of COVID-19. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S301. doi: 10.1016/j.jval.2022.09.1486

Rothwell B, Kiff C, Ling C, Brodtkorb T-H. Cost effectiveness of nivolumab in patients with advanced, previously treated squamous and non-squamous non-small-cell lung cancer in England. Pharmacoecon Open. 2021 Jun;5(2):251-60. doi: 10.1007/s41669-020-00245-4

Popat S, Tanna N, Hartridge-Lambert S, Kiff C, Sowdani A, Rothwell B, Brodtkorb T-H, Ling C, Smittenaar R, Bomb M, Turnbull A. Nivolumab in second line non-small cell lung cancer – comparing real-world outcomes in England to CheckMate (CM) 017 and 057. Poster presented at the IASLC 2020 Virtual World Conference on Lung Cancer; January 28, 2021.

Aronsson M, Ling C, Stevenson A, Brodtkorb TH. Submission process and requirements of Nordic health technology assessment (HTA) authorities for hospital drugs - implications for market access strategy. Poster presented at the ISPOR 2019 European Conference; November 4, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Pearson I, Stevenson A, Krieger T, Ling C. What is the role of the company evidence submission in National Institute for Health and Care Excellence (NICE) multiple technology appraisals? Poster presented at the ISPOR 2019 European Conference; November 5, 2019. Copenhagen, Denmark. [abstract] Value Health. 2019 Dec; 22(S3).

Stevenson A, Carter K, Millar (Gildea) L, Ling C. NICE: a multiprogram HTA organization to suit all? Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.

Stevenson A, Ling C, Unsworth H. The rise of NICE advice on the use of pharmaceuticals, medical devices and digital health care in the NHS. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.

Richardson TD, Ling C. Patient access to new medicines: the changing landscape. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 12, 2018. Barcelona, Spain.

Ling C, Nuabor W, Lyall M, Stevenson A. Review of possible causes of variation in National Institute for Health and Care Excellence (NICE) technology appraisals. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain. [abstract] Value Health. 2018 Oct; 21(Suppl 3):S200.

Fischer A, Zimovetz E, Ling C, Esser D, Shoof N. Humanistic and cost burden of systemic sclerosis: a review of the literature. Autoimmun Rev. 2017 Nov;16(11):1147-54. doi: 10.1016/j.autrev.2017.09.010

Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis. Curr Med Res Opin. 2017 Aug;33(8):1457-66. doi: 10.1080/03007995.2017.1325730

Chirila C, Mitra D, Colosia A, Ling C, Odom D, Iyer S, Kaye JA. Efficacy of palbociclib combinations versus endocrine therapies in advanced/ metastatic breast cancer: network meta-analysis. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 2, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A710.

Boysen M, Tyas D, Ling C, Wolowacz S. The new NICE cancer drugs fund technology appraisal process: your questions answered. Presented at the 2016 ISPOR 19th Annual European Congress; October 31, 2016. Vienna, Austria.

Vickers AD, Ainsworth C, Mody R, Bergman A, Ling CS, Medjedovic J, Smyth M. Systematic review with network meta-analysis: comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis. PLoS One. 2016 Oct 24;11(10):e0165435. doi: 10.1371/journal.pone.0165435

Vickers AD, Mody R, Bergman A, Ling CS, Ainsworth C, Medjedovic J, Smyth M. Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis (UC): a systematic review and network meta-analysis. Poster presented at the 2015 Digestive Disease Week; May 2015. Washington, DC. [abstract] Gastroenterology. 2015 Apr 16; 148(4, Suppl 1):S272. Previously presented at the 10th Congress of the European Crohn's and Colitis Organization.

Vickers AD, Mody RR, Bergman A, Ling CS, Ainsworth C, Medjedovic J, Smyth M. Comparative efficacy of biologics in the treatment of moderately to severely active ulcerative colitis (UC): a systematic review and network meta-analysis. Poster presented at the 10th Congress of the European Crohn's and Colitis Organization; February 18, 2015. Barcelona, Spain. [abstract] J Crohns Colitis. 2015 Feb 2; 9(Suppl 1):S357-8. doi: 10.1093/ecco-jcc/jju027.672

Hogue SL, Bjoerk B, Walker A, Balp M, Fernandez MM, Quijano M, Ling CS, Heyes AE. Evidence-based market access value resource: navigating the hurdles for a biologic obtaining a license in a second indication in key European countries. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam. [abstract] Value Health. 2014 Nov; 17(7):A431-2.

Ling CS, Heyes AE. Pricing and reimbursement environment for a biologic obtaining a licence in a second indication in key European countries. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.

Woods MS, Kiri S, Ling CS, McCrink L, Zimovetz E, Hass B. A systematic review of economic evidence in hepatitis c: methods used in recent economic evaluations. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A579.

Woods MS, Kiri S, Ling CS, McCrink L, Zimovetz E, Hass B. A systematic review of economic evidence in hepatitis c: an overview of cost, utility, and cost-effectiveness data. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A349.

Ainsworth C, Kiri S, Ling CS, Heyes AE, Hass B. The global burden, incidence, and prevalence of chronic hepatitis c. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A342.

Ling CS, Weisgerber-Kriegl U, Njue AI, Heyes A, Kaye J. The effect of positive margins on outcomes in breast cancer. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A394.

DiBenedetti D, Coles T, Ling CS, Sharma T, Pericleous L. Web-based study of patients and caregivers in the United States and Canada: perspectives on improvements in stability of factor viii products for hemophilia a. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 30, 2013. [abstract] Value Health. 2013 May; 16(3):A121.

Sennfalt K, Ling CS, Pericleous L, Sbarigia U, Gatta F, Kolasa K, Chamberlain G, Pandit P, Zagorska G. The economic burden of post-transplant events in renal transplant patients in UK, Italy, Netherlands, Poland and Belgium. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research; 2011. [abstract] Value Health. 2011 Nov; 14(7):A262-3.